Department of Biosciences, University of Milan, Milan, Italy.
Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy.
Cell Mol Life Sci. 2024 Aug 7;81(1):333. doi: 10.1007/s00018-024-05382-1.
Synaptic dysfunction is an early pathogenic event leading to cognitive decline in Huntington's disease (HD). We previously reported that the active ADAM10 level is increased in the HD cortex and striatum, causing excessive proteolysis of the synaptic cell adhesion protein N-Cadherin. Conversely, ADAM10 inhibition is neuroprotective and prevents cognitive decline in HD mice. Although the breakdown of cortico-striatal connection has been historically linked to cognitive deterioration in HD, dendritic spine loss and long-term potentiation (LTP) defects identified in the HD hippocampus are also thought to contribute to the cognitive symptoms of the disease. The aim of this study is to investigate the contribution of ADAM10 to spine pathology and LTP defects of the HD hippocampus. We provide evidence that active ADAM10 is increased in the hippocampus of two mouse models of HD, leading to extensive proteolysis of N-Cadherin, which has a widely recognized role in spine morphology and synaptic plasticity. Importantly, the conditional heterozygous deletion of ADAM10 in the forebrain of HD mice resulted in the recovery of spine loss and ultrastructural synaptic defects in CA1 pyramidal neurons. Meanwhile, normalization of the active ADAM10 level increased the pool of synaptic BDNF protein and activated ERK neuroprotective signaling in the HD hippocampus. We also show that the ADAM10 inhibitor GI254023X restored LTP defects and increased the density of mushroom spines enriched with GluA1-AMPA receptors in HD hippocampal neurons. Notably, we report that administration of the TrkB antagonist ANA12 to HD hippocampal neurons reduced the beneficial effect of GI254023X, indicating that the BDNF receptor TrkB contributes to mediate the neuroprotective activity exerted by ADAM10 inhibition in HD. Collectively, these findings indicate that ADAM10 inhibition coupled with TrkB signaling represents an efficacious strategy to prevent hippocampal synaptic plasticity defects and cognitive dysfunction in HD.
突触功能障碍是导致亨廷顿病(HD)认知能力下降的早期致病事件。我们之前报道过,HD 皮质和纹状体中活性 ADAM10 水平升高,导致突触细胞黏附蛋白 N-钙黏蛋白的过度蛋白水解。相反,ADAM10 抑制具有神经保护作用,并可防止 HD 小鼠的认知能力下降。尽管皮质-纹状体连接的破坏与 HD 认知能力下降有关,但在 HD 海马体中发现的树突棘丢失和长时程增强(LTP)缺陷也被认为是导致该疾病认知症状的原因之一。本研究旨在探讨 ADAM10 对 HD 海马体的棘突病理学和 LTP 缺陷的贡献。我们提供的证据表明,两种 HD 小鼠模型的海马体中活性 ADAM10 增加,导致 N-钙黏蛋白的广泛蛋白水解,N-钙黏蛋白在棘突形态和突触可塑性方面具有广泛的作用。重要的是,HD 小鼠前脑条件性杂合缺失 ADAM10 导致 CA1 锥体神经元的棘突丢失和超微结构突触缺陷得到恢复。同时,ADAM10 活性水平的正常化增加了突触 BDNF 蛋白的池,并激活了 HD 海马体中的 ERK 神经保护信号。我们还表明,ADAM10 抑制剂 GI254023X 恢复了 LTP 缺陷,并增加了富含 GluA1-AMPA 受体的蘑菇棘突在 HD 海马神经元中的密度。值得注意的是,我们报告称,向 HD 海马神经元给予 TrkB 拮抗剂 ANA12 会降低 GI254023X 的有益作用,表明 BDNF 受体 TrkB 有助于介导 ADAM10 抑制在 HD 中发挥的神经保护作用。总之,这些发现表明,ADAM10 抑制与 TrkB 信号的结合代表了一种有效的策略,可以预防 HD 中海马突触可塑性缺陷和认知功能障碍。